Dimerix has granted Everest Medicines the exclusive rights to commercialize DMX 200 in China, South Korea, and parts of Southeast Asia, covering numerous territories. The partnership involves an upfront payment of US$10 million and potential milestones totaling up to US$330 million.
Company Information
Company
Dimerix Limited
Location
Melbourne, Victoria, Australia
About
Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix' lead candidate is in Phase 3 clinical trials for a rare type of kidney disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.
MelbourneBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma